VOICE trial win gives Vafseo a hospitalization claim vs. ESAs; whether that converts to durable share against entrenched generic-ESA economics is the bet

Akebia is a commercial-stage biopharmaceutical company whose lead product, Vafseo, treats anemia in dialysis patients and is already approved, though a recent trial showed it may reduce hospitalizations compared to existing treatments.

Vafseo (vadadustat), an oral HIF-prolyl hydroxylase inhibitor for dialysis-dependent anemia, posted a statistically significant superiority result over ESAs in the 2,116-patient VOICE trial, driven by fewer hospitalizations. The thesis resolves on whether that clinical differentiation translates into commercial traction before Auryxia's collapse erodes the cash base funding the launch. The approval-path risk is structurally unusual: Vafseo already carries a boxed warning from its original NDA, so any safety signal in the VOICE label update could blunt the hospitalization narrative.